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A B S T R A C T
Background
Severe sepsis and septic shock are leading causes of death in the intensive care unit (ICU), despite advances in the treatment of patients
with severe sepsis and septic shock, including early recognition, appropriate treatment with antibiotics and support of organs that may
have been affected by the illness. High-volume haemofiltration (HVHF) is a blood purification technique that may improve outcomes
in severe sepsis or septic shock. The technique of HVHF has evolved from renal replacement therapies used in the ICU to treat critically
ill patients with acute kidney injury (AKI). This review was first published in 2013 and was updated in 2016.
Objectives
To investigate whether HVHF improves outcomes in critically ill adults admitted to the intensive care unit with severe sepsis or septic
shock. The primary outcome of this systematic review is patient mortality; secondary outcomes include duration of stay, severity of
organ dysfunction and adverse events.
Search methods
For this updated version, we extended searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE,
Embase, Latin American Caribbean Health Sciences Literature (LILACS), Web of Science and the Cumulative Index to Nursing and
AlliedHealth Literature (CINAHL) to 31 December 2015. The original search was performed in 2011. We also searched trials registers.
Selection criteria
We included randomized controlled trials (RCTs) and quasi-randomized trials comparing HVHF or high-volume haemodiafiltration
versus standard or usual dialysis therapy, as well as RCTs and quasi-randomized trials comparing HVHF or high-volume haemodiafil-
tration versus no similar dialysis therapy. These studies involved adults treated in critical care units.
Data collection and analysis
Three review authors independently extracted data and assessed trial quality.We sought additional information from trialists as required.
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Main results
We included four randomized trials involving 200 participants. Owing to small numbers of studies and participants, it was not possible
to combine data for all outcomes. Two trials reported 28-day mortality, and one trial reported hospital mortality; in the third trial, the
number of deaths stated did not match the quoted mortality rates. The pooled risk ratio (95% confidence interval) for 28-day mortality
associated with HVHF was 0.89 (0.60 to 1.32, two trials, 146 participants, low-quality evidence). One study (137 participants, low-
quality evidence) reported length of stay in the ICU. Two trials (170 participants, low-quality evidence) reported organ dysfunction,
but we could not pool results owing to reporting differences. Three studies (189 participants, low-quality evidence) reported on
haemodynamic changes, but we could not pool results owing to reporting differences. Investigators reported no adverse events. Overall,
the included studies had low risk of bias.
Authors’ conclusions
Investigators reported no adverse effects of HVHF (low-quality evidence). The results of this meta-analysis show that very few studies
have been conducted to investigate the use of HVHF in critically ill patients with severe sepsis or septic shock (four studies, 201
participants, low-quality evidence). Researchers should consider additional randomized controlled trials that are large and multi-centred
and have clinically relevant outcome measures. The cost-effectiveness of HVHF should also be studied. .
P L A I N L A N G U A G E S U M M A R Y
High-volume haemofiltration for sepsis
Background
Severe sepsis and septic shock are among the most common causes of death in adults admitted to an intensive care unit (ICU). Sepsis
often arises after infection, when the body responds by producing chemicals that cause massive inflammation throughout the body.
This inflammation can cause organs such as kidneys, heart, circulation or lungs to fail. It is these organ failures, which result from
inflammation, that lead to the high death rates associated with sepsis.
Theoretically, if it were possible to artificially neutralize or remove these chemicals from the bloodstream, patient outcomes (such as organ
failure and death) might improve. High-volume haemofiltration (HVHF) is one method that could be used. Standard haemofiltration
is a treatment already used in the ICU to remove toxins that build up when a patient’s kidneys have stopped working. This treatment
involves removal of blood from the patient via a large catheter (a hollow, flexible tube placed into a large vein). After the blood has
been removed, it is passed through a filter that removes toxins. The ’purified’ blood is then returned to the patient via the catheter.
HVHF, a more intense form of this treatment, aims to remove evenmore toxins (including some of the toxic chemicals produced during
sepsis). However, HVHF presents potential disadvantages. This specialized technique requires specific equipment and extra training.
Theoretically, it could have harmful effects on a patient’s blood pressure or could remove beneficial chemicals (such as antibiotics).
For this review, we assessed whether high-volume haemofiltration improves outcomes such as risk of death among patients with severe
sepsis.
Study characteristics
This review is current until December 2015. We included four trials involving 205 participants. All four studies assessed effects of
HVHF compared with the current standard haemofiltration and included participants with severe sepsis or septic shock who had been
admitted to an ICU. Three of the four studies were very small (fewer than 20 participants enrolled in each study). The maximum
time that participants were followed up after inclusion in any of the studies was 28 days. Two studies received financial support from
pharmaceutical companies, and one study received support from a health research organization.
Key results
Outcome data were limited - two trials reported death rates at 28 days and one reported death rates in hospital; in the fourth study, the
number of deaths stated did not match the quoted mortality rates. One study reported length of stay in the ICU, and one provided
data on organ dysfunction. Investigators described no complications.
No clear evidence showed any benefit of HVHF in critically ill patients with severe sepsis or septic shock.
Quality of evidence
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Evidence is insufficient to support the routine use of high-volume haemofiltration in patients with severe sepsis or septic shock. Studies
included in this review reported relatively small numbers of participants and measured different outcomes; therefore, we judged the
quality of evidence with respect to the impact of HVHF as low. Larger trials, carried out at many centres, are required for full assessment
of clinically relevant outcomes and for evaluation of cost versus benefit.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Should high-volume haemofiltration vs standard or usual dialysis be used for sepsis?
Patient or population: pat ients with sepsis
Settings: ICUs in France, Belgium and the Netherlands
Intervention: high-volume haemof ilt rat ion
Comparison: standard or usual dialysis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of evidence
(GRADE)
Assumed risk Corresponding risk
Standard or usual dialysis High-volume haemofiltra-
tion
ICU mortality Study population RR 0.59
(0.19 to 1.59)
19
(1 study)
Lowa
600 per 1000 354 per 1000
(114 to 954)
28-Day mortality Study population RR 0.89
(0.60 to 1.32)
156
(2 studies)
Lowb
500 per 1000 445 per 1000
(300 to 660)
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HR: hazard rat io; RR: risk rat io.
aDowngraded two levels to low quality owing to study heterogeneity and imprecision.
bDowngraded two levels to low quality owing to study heterogeneity and imprecision.
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B A C K G R O U N D
Description of the condition
Sepsis is the body’s response to infection. Sepsis is ‘severe’ when
infection leads to organ dysfunction or failure. Septic shock is
present when infection causes acute circulatory failure that leads
to persistent hypotension despite adequate fluid resuscitation.
Severe sepsis and septic shock are leading causes of the multiple
organ dysfunction syndrome, as well as death, in the intensive care
unit (ICU). Associated mortality remains very high, ranging from
30% to 50% (Surviving Sepsis Campaign 2008) despite advances
in the treatment of patients with severe sepsis and septic shock, in-
cluding early recognition, source control, timely and appropriate
administration of antimicrobial agents and goal-directed haemo-
dynamic, ventilatory and metabolic therapies (Alejandria 2010;
Annane 2004; Gomes Silva 2010; Martí-Carvajal 2011).
The number of patients with severe sepsis and septic shock con-
tinues to grow and is estimated to increase in the United States
(USA) by a rate of 1.5% per year. To the current annual incidence
of 3.0 cases per 1000 of the population, this would add an addi-
tional one million cases per year in the USA alone by 2020 (Angus
2001). This increase is thought to be due to rising numbers of
elderly and high-risk patients in the population and growing use
of invasive procedures within hospital settings (Surviving Sepsis
Campaign 2008).
Our understanding of the complex pathophysiology of sepsis is
evolving. The sepsis syndrome is no longer seen just as a disorder
of uncontrolled inflammation; it is regarded more as a syndrome
reflecting loss of balance between pro-inflammatory and anti-in-
flammatory mediators (Hotchkiss 2003) resulting in organ dam-
age and development of the multiple organ dysfunction syndrome
with its associated high mortality. The sepsis syndrome can oc-
cur with or without acute kidney injury (AKI; formerly known as
acute renal failure (ARF)).
It was once thought that immunological events in sepsis lead to el-
evated levels and activity of inflammatory mediators, and that the
resulting cascade attempts to restore immunological homeostasis
(Adrie 2000). Attempts were made to halt this ’inflammatory cas-
cade’ by blocking or antagonizing single inflammatory mediators.
This did not lead to improvement in outcomes for patients with
sepsis/septic shock (Abraham 2000). It is increasingly recognized
that the systemic inflammatory reaction that characterizes sep-
sis involves very complex interactions between endothelial cells,
platelets, leucocytes, the coagulation system and multiple inflam-
matorymediators (Joannidis 2009). Itwould appear that the initial
concept of sepsis as a stepwise progression down an inflammatory
cascade of mediator release is an oversimplification. In addition to
the pro-inflammatory systemic inflammatory response syndrome
(SIRS) reaction (marked by overproduction of mediators such as
interleukin-1, interleukin-6, interleukin-8 and tumour necrosis
factor-α), sepsis comprises a ‘hyporesponsive’ component. This
excessive anti-inflammatory counterpart to sepsis is referred to as
the ‘compensated anti-inflammatory response syndrome’ (CARS)
(Ronco 2003). The SIRS and CARS components may happen in
sequence (as in ‘the sequential or serial sepsis theory’), with pro-
inflammatory and anti-inflammatory mediators alternatively pro-
duced during high-generation or low-generation periods, leading
to SIRS or CARS, or both. Alternatively, SIRS and CARS may
occur simultaneously (as described in ‘the parallel sepsis theory’)
(Ronco 2003).
Managing these excessive inflammatory and counter inflamma-
tory responses while restoring balance to the immune system is an
important therapeutic goal in the management of severe sepsis/
septic shock.
Description of the intervention
Continuous haemofiltration has been used for some time to treat
critically ill patients with AKI who require renal replacement ther-
apy. This blood purification technique involves removing water
and solutes from the patient’s blood by convection by applying
positive hydrostatic pressure across a filter membrane. In con-
trast, haemodialysis utilizes the process of diffusion. The fluid re-
moved during haemofiltration, which contains water and solutes,
is known as ’ultrafiltrate’. The volume of ultrafiltrate removed dur-
ing the process of continuous haemofiltration can vary depend-
ing on how the clinician prescribes treatment. The amount of
ultrafiltrate removed by this treatment is described in millilitres
(mL) of fluid per kilogram (kg) of the patient’s body weight per
hour (i.e. mL/kg/h). The ’standard’ ultrafiltrate volume removed
can be considered between 25 and 35 mL/kg/h. In ’high-volume’
haemofiltration, the ultrafiltration volume is greater than 35 mL/
kg/h (Ronco 2000).
How the intervention might work
Pro-inflammatory and anti-inflammatory mediators involved in
the sepsis syndrome can be found in the ultrafiltrate of patients
who have received continuous haemofiltration (De Vriese 1999).
It has been suggested that potential clinical benefit may result
from the non-specific reduction in peak concentrations of these
mediators (Ronco 2001) that is achieved by increasing the volume
of ultrafiltrate removed to levels above those used to treat patients
with AKI.
Why it is important to do this review
The technical requirements of high-volume haemofiltration
(HVHF), including tightly controlled blood flow and ultrafiltra-
tion rates, good central venous vascular access, continuous antico-
agulation and use of large amounts of sterile fluid, are both prob-
lematic and demanding for ICU staff. High-volume haemofiltra-
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tion may also be associated with increased, and unmeasured, re-
moval of potentially beneficial substances such as medications or
trace elements. The impact of these losses on patient outcomes
is uncertain. In addition, considerable financial cost is associated
with this procedure, and it is uncertain whether this relatively new
technology offers clinically important benefit for patients with se-
vere sepsis or septic shock (Reiter 2002).
O B J E C T I V E S
To investigate whether HVHF improves outcomes in critically ill
adults admitted to the intensive care unit with severe sepsis or
septic shock. The primary outcome of this systematic review is
patient mortality; secondary outcomes include duration of stay,
severity of organ dysfunction and adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) and quasi-ran-
domized trials (trials in which themethod of allocation is not truly
random but could rely, for example, on allocation by date of birth)
comparingHVHFor high-volume haemodiafiltration versus stan-
dard or usual dialysis therapy; and RCTs and quasi-randomized
trials comparing HVHF or high-volume haemodiafiltration ver-
sus no similar dialysis therapy.
We defined quasi-randomized trials as those involving a method
of allocation to study groups that was not truly random (e.g. by
alternating allocation to treatment or control groups on the basis
of the order of inclusion into the study).
We included only studies that clearly stated the dosage of high-
volume ultrafiltration used.
We excluded studies that did not report the primary outcome as
detailed below.
We did not include conference proceedings and meeting abstracts
in this review.
Types of participants
We included studies of adults aged 16 years and older with severe
sepsis or septic shock in an ICU setting.We accepted study authors’
definitions of severe sepsis and septic shock. We included both
patients with severe sepsis or septic shock and AKI and those with
severe sepsis or septic shock but without AKI. We accepted study
authors’ definitions of AKI.
We excluded studies with participants younger than 16 years of
age, those with participants without severe sepsis or septic shock
and those not conducted in an ICU setting.
Types of interventions
High-volume haemofiltration (or haemodiafiltration) defined as
haemofiltration (or haemodiafiltration) in which an ultrafiltra-
tion rate greater than 35 mL/kg/h was achieved. High-volume
haemofiltration (or haemodiafiltration) was the experimental in-
tervention.
Participants in the control intervention group were those who re-
ceived ‘standard or usual’ dialysis therapy (continuous or inter-
mittent haemofiltration, haemodiafiltration or haemodialysis) and
those who received no similar dialysis therapy.
We accepted the study authors’ definitions of pulse (if applicable)
and continuous high-volume haemofiltration (or haemodiafiltra-
tion).
Types of outcome measures
Primary outcomes
Mortality
1. ICU or hospital mortality, or both, with death reported at 7,
28 or 30 days
Secondary outcomes
Length of stay
1. Length of ICU stay
2. Length of hospital stay
Organ dysfunction
3. Duration of organ dysfunction
4. Number of organ dysfunctions
Adverse effects
5. Risk of haemodynamic changes during HVHF (systolic blood
pressure (SBP), diastolic blood pressure (DBP), mean arterial pres-
sure (MAP), inotrope or vasopressor medication dose change)
6. Risk of central venous catheter-related infection (attributable
to the catheter used for HVHF)
7. Risk of mechanical complications related to catheter placement:
malpositioned lines, haematoma, pneumothorax
8. Risk of bleeding related to anticoagulation
We planned to present pooled estimates of risk (with associated
95%confidence intervals) for all outcomemeasures in a ’Summary
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of findings’ table. We planned to assess the quality of evidence
provided by included studies for each outcome measure using the
GRADE Working Group system.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL; 2015, Issue 12); MEDLINE (Ovid SP, 1990 to
December 2015); Embase (Ovid SP, 1990 to December 2015);
Latin American Caribbean Health Sciences Literature (LILACS)
via BIREME (1982 to December 2015); the Institute for Scien-
tific Information (ISI) Web of Science (1990 to December 2015);
and theCumulative Index toNursing and AlliedHealth Literature
(CINAHL) via EBSCO host (1982 to December 2015).
We developed a search strategy to define keywords for all searches.
See Appendix 1 for the MEDLINE search, Appendix 2 for the
Embase search, Appendix 3 for the CENTRAL search, Appendix
4 for the LILACS search, Appendix 5 for the CINAHL search and
Appendix 6 for the Web of Science search.
In addition, we searched for relevant ongoing trials on specific
websites (31 December 2015).
1. www.controlled-trials.com.
2. www.clinicalstudyresults.org.
3. www.update-software.com.
Searching other resources
When appropriate, we contacted the first authors of studies in-
cluded in the review to obtain further information on unpublished
studies or work in progress. We did not apply language or publi-
cation restrictions.
Data collection and analysis
Selection of studies
Two review authors (EMJB and KSR) independently assessed all
titles and abstracts. We obtained full papers for studies that might
have fulfilled the inclusion criteria.We (EMJB and KSR) indepen-
dently assessed these studies to determine whether they fulfilled
the inclusion criteria. When necessary, we planned to resolve dis-
agreements by discussion and, if necessary, through the decision
of a third review author (APM).
Data extraction and management
Two review authors (EMJB and CJH) independently extracted
data using a modified version of the data extraction form of the
Cochrane Anaesthesia, Critical and Emergency Care Group, as
given in Appendix 7.We resolved disagreements by discussion and
were not blinded with regard to the names of study authors, in-
vestigators or institutions, nor to study results. We listed excluded
trials and reasons for exclusion. We piloted the data extraction
form before use.
Assessment of risk of bias in included studies
Two review authors (EMJB, CJH) independently assessed risk of
bias of included studies by addressing six specific domains (ran-
dom sequence generation, allocation concealment, blinding, in-
complete outcome data, selective reporting and other issues), as
set forth in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). We resolved disagreements by discussion
and planned to involve a fourth review author (APM) should this
be necessary.
Each domain included specific entries in a ‘Risk of bias’ table. We
assessed risk of bias as ’low’, ’high’ or ’unclear’. We contacted the
first authors of included studies for further information on study
design when we judged this to be necessary. We created plots of
the risk of bias in RevMan 5.3.
Measures of treatment effect
We included and combined data using RevMan 5.3, when appro-
priate, by intervention, outcome and population.
For dichotomous data, we used risk ratios (RRs) with 95% confi-
dence intervals (CIs).
For continuous data, we used, as appropriate, mean differences
(MDs) with 95% CIs or standard mean differences (SMDs).
Unit of analysis issues
We had no unit of analysis issues.
Dealing with missing data
We contacted the original investigators to request missing data.
We planned tomake explicit assumptions about anymethods used
to cope with missing data, for example, that the data are assumed
missing at random, or that missing values are assumed to have a
particular value such as a poor outcome. This approach reflects
the guidelines set forth in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We planned to test statistical heterogeneity by using the I2 statis-
tic. We planned to pool clinically and statistically homogeneous
studies using the fixed-effect model. We planned to pool clinically
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homogeneous and statistically heterogeneous (I2 statistic > 50%)
studies using the random-effects model, if appropriate, as set forth
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
We planned to assess clinical heterogeneity by judgement and to
attempt to calculate pooled summary effects only in the absence
of clinical heterogeneity.
Assessment of reporting biases
If sufficient studies were identified, we planned to construct funnel
plots (trial effect vs standard error) to assess possible publication
bias.
Data synthesis
We combined data, when possible, using random-effects models
and assessed heterogeneity using the I2 statistic, as described above.
We reported the main outcomes of this review in Summary of
findings for the main comparison. We incorporated the GRADE
approach to interpret findings andused theGRADEprofiler to im-
port data from RevMan 5.3 to help to create Summary of findings
for the main comparison. We included the following outcomes in
Summary of findings for the main comparison.
1. ICU mortality.
2. 28-Day mortality.
3. Hospital mortality.
Subgroup analysis and investigation of heterogeneity
If adequate data were available, we planned to perform a priori
subgroup analysis for the following categories.
1. Patients with severe sepsis or septic shock and AKI and
those with severe sepsis or septic shock but without AKI.
2. Pulse HVHF and continuous HVHF.
3. Dosage of high-volume ultrafiltration used.
4. Type of ICU: surgical (including cardiac and trauma),
medical or mixed (including all patient categories).
Sensitivity analysis
If appropriate, we planned to perform a sensitivity analysis to look
at review results with and without studies that we deemed to have
high risk of bias.
R E S U L T S
Description of studies
See Figure 1.
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Figure 1. Study selection flow diagram.
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Results of the search
For our published review (Borthwick 2013), the combined search
of MEDLINE, Embase, CINAHL and CENTRAL yielded 1282
potentially relevant studies. After reviewing titles and abstracts,
we excluded 1253 studies. We retrieved the full-text versions of
29 studies, and we excluded 26 of these study reports. The major
reason for exclusion was that identified studies were not random-
ized, or that participants were not appropriate. Examples of inap-
propriate participants included patients with pancreatitis, patients
with AKI who were not all septic and patients with AKI plus non-
renal organ failure who were not necessarily septic. One study was
published as an abstract (Zainudin 2006) and as a paper with a
different first author (Ghani 2006). We included the full paper.
The updated search fromAugust 2011 toDecember 2015 revealed
309 additional potentially relevant studies. We retrieved the full-
text versions of five studies. We excluded four of these studies as
theywere systematic reviews, provided inappropriate interventions
or enrolled inappropriate participants. Finally, we included in the
qualitative synthesis four studies (Boussekey 2008; Cole 2001;
Ghani 2006; Joannes-Boyau 2013) published in five reports with
a total of 200 participants. We reported in the Characteristics of
included studies table the characteristics of populations and inter-
ventions described in the included trials.
We contacted the first author of three studies (Boussekey 2008;
Cole 2001; Ghani 2006) to ask for further information on the
randomization process and the outcome measures described. All
three study authors gave expanded details of the randomization
process, and two study authors provided further information on
and clarification of outcome measures. Joannes-Boyau 2013 pro-
vided sufficient information in the published material on the ran-
domization process used in this study.
Included studies
Only four studies with 200 participants met the entry criteria
for this updated systematic review (Boussekey 2008; Cole 2001;
Ghani 2006; Joannes-Boyau 2013).
Boussekey 2008 was a single-centre randomized controlled trial
that investigated vasopressor doses and other clinical outcomes,
such asmortality, in 19 participants over a 28-day period following
study inclusion. The mean age of participants was 68 years, and
78% were male. Investigators compared HVHF (65 mL/kg/h)
versus control (35 mL/kg/h).
Cole 2001 was a single-centre randomized cross-over trial that
investigated haemodynamic changes and plasma concentrations of
inflammatory mediators in 11 participants over a 48-hour period
following study inclusion. The mean age of participants was 63.1
years, and 73% were male. Investigators compared HVHF (6000
mL/h for 8 hours) versus control (1000 mL/h for 8 hours).
Ghani 2006 was a single-centre parallel randomized controlled
trial that investigated haemodynamic status, inflammatory medi-
ator concentrations and organ dysfunction scores in 33 partici-
pants. The mean age of participants was 58 years, and 53% were
male. Investigators compared HVHF (6000 mL/h for 6 hours)
versus control (2000 mL/h for 6 hours).
Joannes-Boyau 2013 was a multi-centre randomized controlled
trial that investigated 28-daymortality andother clinical outcomes
in 137 participants. The mean age of participants was 68 years,
and 68% were male. Investigators compared HVHF (70 mL/kg/
h for 96 hours) versus control (35 mL/kg/h for 96 hours).
For full details, see Characteristics of included studies.
Excluded studies
We excluded 32 studies from the analysis. For details of ex-
cluded studies, see Characteristics of excluded studies. Nine were
not RCTs (Bellomo 2009; Bouman 2007; Castro 2008; Clark
2014; Honore 2003; Honore 2004; Honore 2007; Honore 2009;
Oudemans-van Straaten1999).
In 10 trials, participants were not appropriate in that they did not
all clearly have severe sepsis or septic shock (Abe 2010; Bouman
2002;Chu2013;Combes 2015;Guo 2014; Palevsky 2008;Ronco
2000; Storck 1991; Yu 2008; Xie 2009).
In 11 cases, the intervention, including high-absorption haemofil-
tration, plasma filtration and high cut-off haemofiltration, was not
appropriate (Haase 2007; Han 2011; Hoffman 1996, Mao 2009;
Morgera 2006; Payen 2009; Peng 2010; Quenot 2015; Wang
2009; Zhang 2004; Zhang 2012).
In one case, the outcome measurement - assessment of acid-base
balance - was not appropriate (Cole 2003). One paper was an ab-
stract for a paper published in full and already included (Zainudin
2006).
Studies awaiting assessment
There are no studies awaiting classification.
Ongoing studies
We found no ongoing studies on HVHF.
Risk of bias in included studies
All included studies were randomized controlled trials; one had a
cross-over design (Cole 2001), and none were quasi-randomized
clinical trials. Figure 2 shows the ’Risk of bias’ summary, andFigure
3 the ’Risk of bias’ graph.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All four included studies had low risk of selection bias in the ran-
dom sequence generation domain. Two studies had low risk of
bias in the allocation concealment domain. One study used sealed
opaque envelopes (Cole 2001), and another used computer-gen-
erated randomized allocation (Joannes-Boyau 2013). One study
had unclear risk of bias (insufficient information available as to the
process of randomization) (Ghani 2006), and another had high
risk of bias (the randomized group for the last participant in each
block was known in advance) (Boussekey 2008).
Blinding
All four included studies had low risk of performance bias. For
outcomes assessed in this review, it was unclear to whom the blind-
ing referred, leading to unclear risk of detection bias in all four
included studies.
Incomplete outcome data
One study had low risk of attrition bias (Cole 2001), and in the
other three studies, this was unclear.
Selective reporting
All four included studies had low risk of reporting bias.
Other potential sources of bias
We found the included studies to be at low risk for other potential
sources of bias.
One study author provided a statement that he had no conflicts
of interest (Boussekey 2008). Two studies reported that inves-
tigators received pharmaceutical company funding (Cole 2001;
Ghani 2006). Cole 2001 stated that this group received phar-
maceutical funding for cytokine and complement measurements
only. Ghani 2006 stated that research was supported by a pharma-
ceutical company grant, but review authors could not determine
the extent of the company’s involvement in the study by reviewing
the manuscript. Joannes-Boyau 2013 stated that one study author
received support from a health research organization.
Effects of interventions
See: Summary of findings for the main comparison Should
high-volume haemofiltration vs standard or usual dialysis be used
for sepsis?
Primary outcomes
Mortality
Boussekey 2008 described ICU mortality of 33.3% (three out of
nine participants) in the treatment intervention group and 60%
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(six out of 10 participants) in the control intervention group (risk
ratio (RR) 0.59, 95% CI 0.19 to 1.59). Investigators reported
28-day mortality of 33.3% (three out of nine participants) in the
treatment intervention group and50%(five out of 10 participants)
in the control intervention group (RR 0.67, 95%CI 0.22 to 2.03).
Joannes-Boyau 2013 described 28-day mortality of 37.9% (25
out of 66 participants) in the treatment intervention group and
40.8% (29 out of 71 participants) in the control intervention
group.Wepooled results fromBoussekey 2008 and Joannes-Boyau
2013 using random-effects modelling and have presented these
results in Figure 4 and in Summary of findings for the main
comparison. The pooled estimate of risk ratio (RR) was 0.89 (95%
CI 0.60 to 1.32, two studies, 156 participants). We classified the
strength of this evidence as low, using the GRADE rating scheme
(grade reduced owing to imprecision).
Figure 4. Forest plot of comparison: 1 Mortality risk, outcome: 1.1 Relative risk of mortality.
One study (Cole 2001) reported only hospital mortality rates,
stated as 54.5% (six out of 11 participants), and as this was a cross-
over study, between-group comparisons were not possible.
The fourth study (Ghani 2006) reported a mortality rate of 76%
(25 out of 33 participants). It was not clear if this referred to
ICU, hospital or other (e.g. 28-day mortality). In addition, closer
examination of the data published in this paper revealed that the
number of deaths stated did not match the quoted mortality rates,
nor was it reflected in the survival function curve. We have not
been able to receive clarification from the study author on this;
therefore, we have not included it in our analysis of mortality.
Secondary outcomes
Length of stay
One study (Joannes-Boyau 2013) investigated length of ICU stay;
researchers reported no difference in the median number of ICU-
free days (75 days in the intervention group and 74 in the control
group).
Organ dysfunction
Investigators in two studies (Ghani 2006; Joannes-Boyau 2013)
stated that they measured the sequential organ failure assessment
score (SOFA score). Ghani 2006 measured SOFA scores at days
zero, one and seven, and at ICU and hospital discharge. The SOFA
scores were similar in treatment and control intervention groups
at baseline and fell in both groups by day seven, with a statistically
significant fall in the control intervention group (P = 0.048 in the
treatment group and P = 0.006 in the control intervention group).
Joannes-Boyau 2013 measured SOFA scores at days four and 28
and reported no difference between median SOFA scores in the
intervention and control groups at either time point. Joannes-
Boyau 2013 also reported the simplified acute physiology score II
(SAPS II) at days four and 28 and revealed no significant difference
at either time point. We downgraded the evidence to low quality
owing to imprecision.
Adverse events
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Haemodynamic change
HVHF did not appear to cause haemodynamic instability in these
studies. In Ghani 2006, study authors stated that they observed no
significant drop in systolic blood pressure (SBP), diastolic blood
pressure (DBP) or mean arterial pressure (MAP) after treatment.
Boussekey 2008 showed that HVHF was associated with a de-
crease in norepinephrine dose greater than 75% in 24 hours in
eight out of nine participants in the treatment intervention group
compared with four out of 10 participants in the control interven-
tion group (RR 2.22, 95% CI 1.01 to 4.51). Similarly, Cole 2001
noted that the dose of norepinephrine required for maintenance
of target MAP during treatment decreased more during HVHF
than during continuous veno-venous haemofiltration (CVVH).
This was a median dose reduction of 10.5 µg/min (interquartile
range (IQR) 11.0) versus 1.0 µg/min (IQR 6.0), for a proportional
decrease of 68% (IQR 28%) versus 7% (IQR 59%). Owing to
differing reporting methods, we were unable to produce pooled
estimates of effect. We downgraded this evidence to low quality
owing to imprecision.
No researchers specifically commented on risk of central venous
catheter-related infection, risk ofmechanical complications related
to catheter placement (malpositioned lines, haematoma, pneu-
mothorax) or risk of bleeding related to anticoagulation. Ghani
2006 stated, “there were no reported cases of excessive bleeding
and adverse side-effects”. Boussekey 2008 reported, “no adverse
event associated with HVHF, like severe hypophosphataemia or
hypokalaemia, was recorded” and Cole 2001 said, “no adverse
events were noted”. Joannes-Boyau 2013 described three serious
adverse events but stated that investigators judged none of these
to have been directly related to the study intervention.
D I S C U S S I O N
Severe sepsis and septic shock are associated with poor patient
outcomes. High-volume haemofiltration (HVHF) has been theo-
rised to confer potential benefit in this setting. This systematic re-
view shows that, despite the potential benefits of HVHF, very few
studies have been conducted to investigate its use in patients with
severe sepsis or septic shock. The studies included in this analysis
included only small numbers of participants and used clinically di-
verse case definitions, treatment strategies and outcome measures.
The clinical heterogeneity of the included studies resulted in dif-
ficulty in pooling estimates for major outcomes. The evidence
presented in Summary of findings for the main comparison and
Figure 4 incorporates data fromonly two studies (Boussekey 2008;
Joannes-Boyau 2013) and therefore should be interpreted with
caution. Joannes-Boyau 2013 stated that the trial was prematurely
terminated because of slow recruitment and, therefore, did not
enrol the anticipated number of participants required to achieve
the desired 85% power. These limited data suggest that HVHF
does not appear to confer improved mortality risk over standard
therapy. Limited evidence also shows a trend towards reduced va-
sopressor requirements in patients treated with HVHF. Boussekey
2008 and Cole 2001 commented on this finding, but differing
methods of reporting precluded the possibility of a pooled esti-
mate. The review authors believe that this updated systematic re-
view has highlighted the continued paucity of evidence in this field
and the need for additional large-scale clinical trials to determine
the effects of HVHF.
Summary of main results
We found very weak evidence to support the use of high-volume
haemofiltration in critically ill patients with severe sepsis/septic
shock to improve outcomes. We found no evidence to suggest that
the treatment intervention was harmful.
Overall completeness and applicability of
evidence
The evidence reported here is weak as a result of the limited num-
ber of trials identified with few participants. Therefore, one must
interpret the results of this review with caution.
Quality of the evidence
Flaws in reporting of outcome results further reduced the data
available for analysis. Clinical heterogeneity in terms of time points
for assessing mortality rates meant that it was difficult to pool
estimates for all primary outcomes. The small number of studies
identified and, in particular, the single-centre nature of three of
the included studies (Boussekey 2008; Cole 2001; Ghani 2006)
meant that review authors had to downgrade the quality of evi-
dence produced in this review to low (reduced by two levels for
imprecision).
Potential biases in the review process
The only potential bias in the review process of which review
authors are aware is that we were unable to receive a response from
the authors of Ghani 2006; this could have biased some of the
results pertaining to mortality. However, given that Ghani 2006
was a small single-centre study, it seems unlikely that the results of
this review would have been significantly altered by its inclusion
in the quantitative synthesis for mortality.
Agreements and disagreements with other
studies or reviews
We are not aware of any similar studies or reviews meeting our
inclusion and exclusion criteria.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence presented in this review, although of low quality,
suggests that HVHF does not provide significant benefit in terms
of reduction in mortality among critically ill patients with severe
sepsis or septic shock.
Implications for research
As noted, the evidence presented in this review is of low quality
owing to the relatively small numbers of participants studied, the
single-centre nature of many studies and the heterogeneity of re-
porting of key outcomes. Future studies should be multi-centre in
nature and sufficiently powered to address key outcomes such as
mortality. These studies should adopt standard definitions for the
critical outcomes measured. For example, researchers should reach
consensus as to the time point for assessing mortality rates, such
as by limiting studies to measuring 28-day mortality from time of
randomization. This would also apply to secondary outcomes for
which studies should adopt standard protocols, for example, for
administration of vasopressor agents, which would allow data to
be pooled across studies. The financial implications of providing
HVHF, including those related to equipment and staffing costs,
should be assessed in a cost-benefit analysis. The review authors
are not aware of any new trials, either registered or ongoing, in-
volving the use of HVHF for sepsis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boussekey 2008
Methods Country: France
Setting: single-centre ICU
Time frame: 18 months (Aug 2005 to Jan 2007)
Parallel RCT
Intention-to-treat analysis: yes
Follow-up period: 28 days
Lost to follow-up:- 0/19
Participants No. randomized: 20
No. analysed: 19
(1 participant in HVHF group secondarily excluded, as diagnosis was mesenteric is-
chaemia rather than septic shock)
Treatment intervention
N = 9
Mean age: 68 years
Male, %: 77.77
Mean SAPS II score: 66
Mean APACHE II score: 32
Control intervention
N = 10
Mean age: 72.5 years
Male, %: 80
Mean SAPS II score: 67
Mean APACHE II score: 33.50
Inclusion criteria
Septic shock and ARF requiring RRT
Exclusion criteria
Obstructive or prerenal renal failure
Severe chronic kidney disease (creatinine clearance < 30 mL/min)
Included in another study
Severe immunosuppression (study authors’ definitions)
Moribund
Decision that therapy was limited
Septic shock or renal failure > 5 days after ICU admission
Absence of written consent
Secondarily excluded if a participant died within first day after randomization or was
found to have a disease other than septic shock
Interventions Treatment intervention
HVHF: 65 mL/kg/h ultrafiltrate flow for maximum of 4 days, or until norepinephrine
was discontinued for at least 4 hours with persistent MAP > 65 mmHg
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Boussekey 2008 (Continued)
Blood flow: 200-300 mL/min
Bicarbonate replacement fluid: replaced one-third pre-filter and two-thirds post-filter
Bicarbonate buffered fluid
Filter: 1.4 m2 polyethersulfone
Control intervention
35 mL/kg/h ultrafiltrate flow for maximum of 4 days, or until norepinephrine was
discontinued for at least 4 hours with persistent MAP > 65 mmHg
Blood flow: 180-250 mL/min
Bicarbonate replacement fluid: replaced one-third pre-filter and two-thirds post-filter
Filter: 1.4 m2 polyethersulfone
Outcomes Vasopressor use with stable MAP (> 65 mmHg) within 24 hours of haemofiltration
Duration mechanical ventilation and RRT
ICU length of stay
Mortality in ICU and day 28
Notes Funding source: Tourcoing Hospital
No conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate: block randomization with se-
quentially number sealed envelopes
Allocation concealment (selection bias) High risk The group for the last participant in each
block was known in advance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind personnel to allocated
treatment, although considered to be at low
risk
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated as for whom or how outcome
assessment was made
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete data were reported.
Selective reporting (reporting bias) Low risk Protocol available and predefined out-
comes reported
Other bias Low risk Appears to be free of other sources of bias
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Cole 2001
Methods Country: Australia
Setting: tertiary-centre ICU
Time frame: unclear
Cross-over RCT
Intention-to-treat analysis: yes
Follow-up period: 2 days
Lost to follow-up: none
Participants No. of participants randomized: 11
No. of participants analysed: 11
Mean age: 63.1
Male, no. (%): 8/11 (73)
Inclusion criteria
Septic shock (criteria of bone)
Established ARF secondary to septic shock (with oliguria or anuria)
Established need for RRT
Recognized source of sepsis that had been treated with antibiotics and surgical drainage
of source if necessary
Exclusion criteria
ESRD
AIDS
Life expectancy < 6 months
Withdrawal of therapy possible
Interventions Treatment intervention
HVHF
8-Hour session
Filter: 1.6 m2 AN 69
Blood flow: 300 mL/min; ultrafiltrate flow: 100 mL/min
Lactate buffered replacement fluid: one-third delivered pre-filter, two-thirds post-filter
Control intervention
CVVH
8-Hour session
Filter: 1.2 m2 AN 69 polyacrylonitrile
Blood flow: 200 mL/min; ultrafiltrate flow: 1 L/h
Lactate buffered replacement fluid delivered pre-filter
MAP to be maintained at > 70 mmHg throughout
Outcomes Mean arterial pressure and norepinephrine dose
Notes Funding source: Austin & Repatriation Medical Centre Anaesthesia and Intensive Care
Trust Fund and Hospal Pty Ltd
No conflicts of interest declared
Risk of bias
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Cole 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generation by computer
programme
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind personnel to allocated
treatment, although considered to be at low
risk
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated as for whom or how outcome
assessment was made
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Protocol available and predefined out-
comes reported
Other bias Low risk Appears to be free of other sources of bias
Ghani 2006
Methods Country: Malaysia
Setting: single centre
Time frame: not stated
Parallel RCT
Intention-to-treat analysis: yes
Follow-up period: not stated
Lost to follow-up: 0/33
Participants No. of participants randomized: 33
No. of participants analysed: 33
3 participants excluded on account of inadequate blood sample collection
Treatment intervention
N = 15
Mean age: 58 years
Male, %: 53.33
Pre-existing CKD: 40%
Diabetes: 46.66%
Baseline MAP: 99.3 mmHg
Control intervention
N = 18
Mean age: 57.50 years
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Ghani 2006 (Continued)
Male, %: 61.11
Pre-existing CKD: 50.00%
Diabetes: 50.00%
Baseline MAP: 87.6 mmHg
Inclusion criteria
Patients who fulfilled criteria for sepsis (study author’s definition) with 1 additionalmajor
end-organ dysfunction or septic shock as defined by the American College of Chest
Physicians/Society of Critical Care Medicine Consensus Conference
Exclusion criteria
ESRD (end-stage renal disease)
Underlying malignancy
AIDS
Life expectancy < 6 months
Interventions Treatment intervention
6 hours of HVHF
Ultrafiltration rate: 6 L/h (equivalent to 100 mL/kg/h, whichever was higher)
Blood flow: 250-350 mL/min
Bicarbonate substitution fluid
1.4 m2 polyethersulfone dialysis membrane
Control intervention
6 hours of CVVH
Ultrafiltration rate: 2 L/h (equivalent to almost 35 mL/kg/h)
Blood flow: 200-250 mL/min
1.4 m2 polyethersulfone dialysis membrane
Outcomes Blood pressure (systolic, diastolic and mean arterial pressure)
SOFA scores
Notes Funding source: Edwards Life Sciences
No conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization carried out
Allocation concealment (selection bias) Unclear risk Insufficient information available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind personnel to allocated
treatment, although considered to be at low
risk
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Ghani 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information available to com-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information available to com-
ment
Selective reporting (reporting bias) Low risk Protocol available and predefined out-
comes reported
Other bias Low risk Appears to be free of other sources of bias
Joannes-Boyau 2013
Methods Country: France, Belgium and Netherlands
Setting: multi-centre ICUs
Time frame: 53 months (October 2005-March 2010)
Parallel RCT
Intention-to-treat analysis: yes
Follow-up period: 90 days
Lost to follow-up: none
Participants No. randomized: 140 (3 excluded, 1 by steering committee for eligibility reason, 2 for
consent reasons)
No. analysed: 137
Treatment intervention
N = 66
Mean age: 68 years
Male, %: 68
SAPS II: 68
Mean APACHE II score: not described
Control intervention
N = 71
Mean age: 70 years
Male, %: 54
Mean SAPS II score: 64
Mean APACHE II score: not described
Inclusion criteria
Septic shock and AKI (scoring ‘INJURY’ or greater in RIFLE criteria)
Exclusion criteria
Age ≥ 80 years
Estimated life expectancy ≤ 3 months
Metastatic cancer
Decompensated cirrhosis
Acute necrotizing pancreatitis
Prior diagnosis of ESRD
Confirmed pregnancy
Severe coagulopathy
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Joannes-Boyau 2013 (Continued)
Lack of commitment to full medical support
Interventions Treatment intervention
HVHF 70 mL/kg/h ultrafiltrate flow for 96 hours
Blood flow: average blood flow rates 200-320 mL/min
Bicarbonate replacement fluid: replaced one-third pre-filter and two-thirds post-filter
Filter: 1.9 m2 polyethersulfone
Control intervention
HVHF 35 mL/kg/h ultrafiltrate flow for 96 hours
Blood flow: average blood flow rates 200-320 mL/min
Bicarbonate replacement fluid: replaced one-third pre-filter and two-thirds post-filter
Filter: 1.9 m2 polyethersulfone
Outcomes Primary endpoint
28-Day mortality
Secondary endpoint
Change in haemodynamic profile
Change in SOFA and SAPS II scores
Duration of mechanical ventilation
Duration of RRT and recovery of renal function
Duration of stay in ICU and hospital
60-Day and 90-day mortality
Adverse events attributable to haemofiltration
Notes Funding source: French Health Ministry
One study author declared an award received from a health research organization
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate: block randomization
Allocation concealment (selection bias) Low risk Adequate: allocation process centralized
and allocation group concealed until im-
plementation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind personnel to allocated
treatment, although considered to be at low
risk
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trained personnel using standardized re-
port form
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete data were reported.
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Joannes-Boyau 2013 (Continued)
Selective reporting (reporting bias) Low risk Protocol available and predefined out-
comes reported
Other bias Low risk Appears to be free of other sources of bias
AKI: acute kidney injury.
AN: acrylonitrile.
APACHE II: Acute Physiology and Chronic Health Evaluation II.
ARF: acute renal failure.
CKD: chronic kidney disease.
CVVH: continuous veno-venous haemofiltration.
ESRD: end-stage renal disease.
HVHF: high-volume haemofiltration.
INJURY: part of RIFLE (see below) criteria for assessment of severity of acute kidney injury.
ICU: intensive care unit.
MAP: mean arterial pressure.
RCT: randomized controlled trial.
RIFLE: “Risk, Injury, Failure, Loss, End-stage” criteria for assessment of severity of acute kidney injury.
RRT: renal replacement therapy.
SAPS: Simplified Acute Physiology Score.
SOFA: Sequential Organ Failure Assessment score.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abe 2010 Type of participant not appropriate (not all septic)
Bellomo 2009 Type of participant not appropriate (not all septic)
Bouman 2002 Type of participant not appropriate (not all septic)
Bouman 2007 Review paper, not a trial report
Castro 2008 Study design not appropriate (an algorithm for use in emergency room)
Chu 2013 Type of participant not appropriate (not all septic)
Clark 2014 Review paper, not a trial report
Cole 2003 Outcome measures not appropriate (outcomes focused on acid base measurements)
Combes 2015 Type of participant not appropriate (not all septic)
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(Continued)
Guo 2014 Type of participant not appropriate (not all septic)
Haase 2007 Type of intervention not appropriate (high adsorption filters under investigation, not HVHF)
Han 2011 Outcome measures not appropriate (outcomes focused on endothelial cell function)
Hoffman 1996 Type of intervention not appropriate (not HVHF)
Honore 2003 Review paper, not a trial report
Honore 2004 Review paper, not a trial report
Honore 2007 Review paper, not a trial report
Honore 2009 Review paper, not a trial report
Mao 2009 Type of intervention not appropriate (not HVHF, plasma adsorption under investigation)
Morgera 2006 Type of intervention not appropriate (not HVHF, high cut-off filters under investigation)
Oudemans-van Straaten1999 Type of participant and study design not appropriate (not all septic, not randomized)
Palevsky 2008 Type of participant not appropriate (not all septic)
Payen 2009 Type of intervention not appropriate (not HVHF)
Peng 2010 Outcome measures not appropriate (outcomes focused on cytokine levels)
Quenot 2015 Type of intervention not appropriate (extra high volume haemofiltration vs HVHF)
Ronco 2000 Type of participant not appropriate (not all septic)
Storck 1991 Type of participant and intervention not appropriate (not all septic, not HVHF)
Wang 2009 Outcome measures not appropriate (outcomes focused on lactic acid and cytokine levels)
Xie 2009 Type of participant not appropriate (not all septic)
Yu 2008 Type of participant not appropriate (not septic, all pancreatitis)
Zainudin 2006 Abstract only, published paper included (different first study author)
Zhang 2004 Outcome measures not appropriate (outcomes focused on cytokine levels)
Zhang 2012 Type of intervention not appropriate (extra high volume haemofiltration vs HVHF)
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HVHF: high-volume haemofiltration.
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D A T A A N D A N A L Y S E S
Comparison 1. Mortality risk
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relative risk of mortality 2 156 Risk Ratio (IV, Random, 95% CI) 0.89 [0.60, 1.32]
Analysis 1.1. Comparison 1 Mortality risk, Outcome 1 Relative risk of mortality.
Review: High-volume haemofiltration for sepsis in adults
Comparison: 1 Mortality risk
Outcome: 1 Relative risk of mortality
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Boussekey 2008 3/9 5/10 12.3 % 0.67 [ 0.22, 2.03 ]
Joannes-Boyau 2013 25/66 29/71 87.7 % 0.93 [ 0.61, 1.41 ]
Total (95% CI) 75 81 100.0 % 0.89 [ 0.60, 1.32 ]
Total events: 28 (Experimental), 34 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Lower Risk Higher Risk
29High-volume haemofiltration for sepsis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid SP) search strategy
#1 (Volume adj10 (ultrafiltrat* or h?emofiltrat*)).mp.
#2 (HVHF or HVHF).ti,ab.
#3 exp Hemodiafiltration/
#4 exp Hemofiltration/ or exp Ultrafiltration/
#5 (Extracorporeal adj10 ultrafiltration).mp.
#6 (h?emofiltrat* or h?emodiafiltrat* or ultrafiltrat*).mp.
#7 (purification adj5 therap*).mp.
#8 (Blood adj5 purificat*).mp.
#9 (purificat* adj3 therap*).mp.
#10 or/1-9
#11 exp Sepsis/ or exp Shock, Septic/
#12 Systemic Inflammatory Response Syndrome/
#13 Multiple Organ Failure/
#14 (multi?organ adj5 failure).mp.
#15 SIRS.mp.
#16 (sepsis* or septic* or SIRS).mp.
#17 or/11-16
#18 #10 and #17
#19 randomised controlled trial.pt.
#20 controlled clinical trial.pt.
#21 randomized.ab.
#22 placebo.ab.
#23 drug therapy.fs.
#24 randomly.ab.
#25 trial.ab.
#26 groups.ab.
#27 or/19-26
#28 humans.sh.
#29 #27 and #28
#30 #18 and #29
Appendix 2. Embase (Ovid SP) search strategy
#1 (Volume adj10 (ultrafiltrat* or h?emofiltrat*)).mp.
#2 (HVHF or HVHF).ti,ab.
#3 exp HEMODIAFILTRATION/
#4 exp HEMOFILTRATION/
#5 exp ULTRAFILTRATION/
#6 (Extracorporeal adj10 ultrafiltration).mp.
#7 (h?emofiltrat* or h?emodiafiltrat* or ultrafiltrat*).mp.
#8 (purification adj5 therap*).mp.
#9 (purificat* adj5 therap*).mp.
#10 or/1-9
#11 exp Sepsis/ or exp Shock, Septic/ or exp Septicemia/
#12 (sepsis* or septic*).mp.
#13 Multiple Organ Failure/
#14 (multi?organ adj6 failure).mp.
#15 or/11-14
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#16 Randomized Controlled Trial/
#17 RANDOMIZATION/
#18 Controlled Study/
#19 Multicenter Study/
#20 Phase 3 Clinical Trial/
#21 Phase 4 Clinical Trial/
#22 Double Blind Procedure/
#23 Single Blind Procedure/
#24 (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*).ti,ab.
#25 ((SINGL* or DOUBL* or TREBL* or TRIPL*) adj6 (BLIND* or MASK*)).ti,ab.
#26 or/16-25
#27 “human*”.ec,hw,fs.
#28 #27 and #26
#29 #28 and #10 and #15
Appendix 3. CENTRAL (the Cochrane Library) search strategy
#1 (HVHF or HVHF):ti,ab
#2 MeSH descriptor Hemodiafiltration explode all trees
#3 MeSH descriptor Hemofiltration explode all trees
#4 MeSH descriptor Ultrafiltration explode all trees
#5 h?emofiltrat* or h?emodiafiltrat* or ultrafiltrat*
#6 purification NEAR therap*
#7 Blood near purificat*
#8 (blood near therap*):ti,ab
#9 (#1 OR #2 OR #3 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Sepsis explode all trees
#11 MeSH descriptor Shock, Septic explode all trees
#12 MeSH descriptor Systemic Inflammatory Response Syndrome explode all trees
#13 MeSH descriptor Multiple Organ Failure explode all trees
#14 sepsis* or septic*
#15 (#10 OR #11 OR #12 OR #13 OR #14)
#16 (#9 AND #15)
Appendix 4. LILACS (BIREME) search strategy
HEMODIAFILTRATION/“ or ”HEMOFILTRATION“ or ”ULTRAFILTRATION/“ or ”haemofiltrat$“ or ”haemodiafiltrat$“ or
”ultrafiltrat*“ or ”purificat$ therap$“ or ”Blood purificat$“ or ”HVHF“ or ”HVHF“ or ”terapia de la purificación“ or ”terapia da
purificação“ or ”Purificação do sangue“ or ”Purificación de la sangre“ [Words] and ”SEPSIS“ or ”SEPSIS SYNDROME/“ or ”SEPTIC
SHOCK/“ or ”SYSTEMIC INFLAMMATORY RESPONSE SYNDROME/“ or ”MULTIPLE ORGAN FAILURE/“ or ”SIRS“ or
”septic$“ or ”sepsis“ or ”Falta múltiple del órgano“ or ”Falha múltipla do órgão“
31High-volume haemofiltration for sepsis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 5. CINAHL (EBSCO host) search strategy
S1 purification therap*
S2 Blood purificat*
S3 MW Hemodiafiltration
S4 MW Hemofiltration
S5 MW Ultrafiltration
S6 S5 or S4 or S3 or S2 or S1
S7 MW Sepsis
S8 MW Shock, Septic
S9 MW Systemic Inflammatory Response Syndrome
S10 TX Multiple Organ Failure
S11 TX multiorgan failure
S12 TX sepsis* or septic* or SIRS
S13 S12 or S11 or S10 or S9 or S8 or S7
S14 S13 and S6
Appendix 6. ISI Web of Science search strategy
#1 TS=(purification SAME therap*) or TS=(Blood SAME purificat*) or TS=(purificat* SAME therap*) or TS=(h?emofiltrat* or h?
emodiafiltrat* or ultrafiltrat*) or TS=(HVHF or HVHF) or TS=(Volume SAME (ultrafiltrat* or h?emofiltrat*))
#2 TS=(sepsis* or septic* or SIRS) or TS=(Systemic Inflammatory Response Syndrome) or TS=(Multiple Organ Failure) or TS=(multi?
organ SAME failure)
#3 #2 AND #1
#4 TS=(random*) or TS=(clinical trial*) or TS=(controlled trial*) or TS=placebo
#5 #4 AND #3
Appendix 7. Data extraction form
Study selection, quality assessment & data extraction form
Name of author extracting data: ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙
Date form completed: ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙
Study ID
Title
Study ID for RevMan
(Family name of first author and year of publication + letter if more than one per year, e.g. Smith 2001b)
Are there other articles on the same study? (Yes, No, Unclear. If Yes, write Study IDs)
Study eligibility
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(please circle) Source (page no. in report)
Type of study
Can the study be described as randomized
or quasi-randomized, i.e. method of allo-
cation
is knownbut study is not considered strictly
randomized?
Yes, Unclear, No
Participants
1. Were participants adults (≥ 16 years) in
ICUs?
2. Did they have severe sepsis or septic
shock (study authors’ definitions)?
Yes, Unclear, No
Yes, Unclear, No
Interventions
1. HVHF0r HVHDF (> 35 mL/kg/h) vs
some form of RRT
OR
2. HVHF or HVHDF(> 35 mL/kg/h) vs
no similar dialysis therapy
Yes, Unclear, No
Yes, Unclear, No
Outcomes: Did the study report any one
of:
1. Mortality rates, ICU or hospital with
deaths reported at 7, 28 or 30 days
Yes, Unclear, No
Conclusion: If study to be ‘included’ or ‘excluded & listed in excluded table’, record
below the information to be inserted into tables. If included, continue to page 2
Included
Excluded and should be listed in the excluded table
Excluded and should NOT be listed in the excluded table
More information needed before inclusion decision (specify)
:
Record for tables:
Source of key information
Electronic database
(Which one?)
Unpublished source
(Where?)
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(Continued)
Personal communication
(From whom?)
Risk of bias table
Domain Description Review authors’ judgement
Randon sequence generation
(selection bias)
Outcome:
Was the allocation (selection bias) sequence adequately generated?
Low risk High risk Unclear risk
Allocation concealment
(selection bias)
Outcome:
Was allocation adequately concealed?
Low risk High risk Unclear risk
Blinding of participants, personnel and
outcome assessors
(performance bias and detection bias)
Outcome:
Wasknowledge of the allocated intervention adequately prevented during
the study?
Low risk High risk Unclear risk
Incomplete outcome data
(attrition bias)
Outcome:
Were incomplete outcome data adequately addressed?
Low risk High risk Unclear risk
Selective outcome reporting
(reporting bias)
Outcome:
Are reports of the study free of suggestion of selective outcome reporting?
Low risk High risk Unclear risk
Other potential sources of bias
Outcome:
Was the study apparently free of other problems that could put it at high
risk of bias?
Low risk High risk Unclear risk
Setting
Country
Setting Single ICU
> 1 ICU (specify no.)
Type of ICU (& no.) Medical
Surgical
Mixed medical and surgical unit
Other (specify)
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Participants
No of participants who were randomized Intervention group n = Control group n =
No of participants who were analysed Intervention group n = Control group n =
Age (mean/SD) Intervention group Control group
Sex of participants
(M/F numbers or %)
Intervention group Control group
Inclusion criteria
Exclusion criteria
Intervention delivery
HVHF
Dose (in mL/kg/h)
Modality
Duration of therapy delivery (hours)
Pulse or continuous
Haemofiltration
Haemodiafiltration
‘Standard or usual’ practice
If RRT:
Dose (mL/kg/h)
Modality
Duration/Frequency
No RRT
Intermittent CRRT
HF HDF HD
Outcomes relevant to the review reported in the paper
Mortality
• ICU survival
• Hospital survival
Yes/No
Yes/No
Length of stay
• Length of ICU stay
• Length of hospital stay
Yes/No
Yes/No
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(Continued)
Organ dysfunction
• Duration of organ dysfunction
• Number of organ dysfunctions
Yes/No
Yes/No
Adverse events:
• Incidence of haemodynamic change when undergoing
HVHF (SBP, DBP, MAP, inotrope/vasopressor dose change)
• Incidence of catheter-related infection rate
• Incidence of mechanical complications related to catheter
placement - malpositioned lines, haematoma, pneumothorax
• Incidence of bleeding related to anticoagulation
Yes/No
Yes/No
Yes/No
Yes/No
Outcomes: continuous data
Outcomes Unit
of measure-
ment
Intervention
group
Control group 95% CI or any
further details if
outcome
described only in
textn Mean
(SD)
Median
(IQR)
n Mean (SD) Median
(IQR)
P value ICU length of stay
Hospital length of
stay
Type + Duration
of organ dysfunc-
tion
Type + Number
of organ dysfunc-
tions
Haemodynamic
change when un-
dergoing HVHF:
SBP
DBP
MAP
Inotrope/
Vasopressor dose
change
Outcomes: dichotomous data
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Outcomes Intervention group
(n = )
Control group
(n = )
P value Any further information
ICU mortality
Hospital mortality
Mechanical
complications related to
catheter placement:
Malpositioned lines
Haematoma
Pneumothorax
Catheter-
related infection (due to
HVHF catheter)
Bleeding related to anti-
coagulation
Please specify the number of participants in each group experiencing specified outcomes.
Other information that you believe is relevant to the results:
Indicate if any data were obtained from the primary author; or if results were estimated from graphs, etc, or were calculated by you
using a formula (this should be stated and the formula given). In general, if results not reported in the paper(s) are obtained, this
should be made clear here to be cited in the review. Freehand space for writing actions such as contact with study authors and changes.
WH A T ’ S N E W
Last assessed as up-to-date: 31 December 2015.
Date Event Description
31 December 2015 New search has been performed This is an update of a previous Cochrane systematic
review that included three RCTs (Borthwick 2013).
The authors of the initial version updated this review.
We used the initial search criteria again but extended
the search date to 31 December 2015. Inclusion and
exclusion criteria remained unchanged from the orig-
inal version
We found only one extra study (Joannes-Boyau 2013)
to include in the quantitative synthesis. We con-
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(Continued)
structed a forest plot by using mortality data
31 December 2015 New citation required but conclusions have not
changed
Overall, the conclusions of this updated review remain
the same, despite the addition of one extra RCT
H I S T O R Y
Protocol first published: Issue 4, 2009
Review first published: Issue 1, 2013
Date Event Description
3 January 2013 Amended We updated contact details.
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